![](/images/graphics-bg.png)
Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators
Joint Authors
Worobetz, Lawrence
Chan, Yin
Pranke, Stephanie
Rashidi, Farid
Nosib, Shravan
Source
Canadian Journal of Gastroenterology and Hepatology
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-02-27
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Background.
Emerging evidence suggests that nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery diseases and arrhythmias.
The FibroScan (Echosens, France), a widely available, noninvasive device, is able to detect liver fibrosis and steatosis within this patient population.
However, the FibroScan is currently contraindicated in patients with cardiac pacemakers (PM) or implantable cardioverter-defibrillators (ICD).
Objective.
To determine the safety profile of FibroScan testing in patients with PM or ICD.
Methods.
Consecutive outpatients undergoing routine device interrogations at a tertiary level teaching hospital underwent simultaneous liver stiffness measurements.
PM or ICD performance data, device types, patient demographics, medical history, and previous laboratory and conventional liver imaging results were collected.
Results.
Analysis of 107 subjects with 33 different types of implanted cardiac devices, from 5 different companies (Medtronic, Sorin, ELA Medical, Boston Scientific, and St.
Jude), did not demonstrate any adverse events as defined by abnormal device sensing/pacing or ICD firing.
This population included high risk subjects undergoing active pacing (n=53) and with right pectoral PM placement (n=1).
None of the subjects had any clinical signs of decompensated congestive heart failure or cirrhosis during the exam.
Conclusion.
TE with FibroScan can be safely performed in patients with PM or ICD.
American Psychological Association (APA)
Chan, Yin& Pranke, Stephanie& Rashidi, Farid& Nosib, Shravan& Worobetz, Lawrence. 2017. Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators. Canadian Journal of Gastroenterology and Hepatology،Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1141461
Modern Language Association (MLA)
Chan, Yin…[et al.]. Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators. Canadian Journal of Gastroenterology and Hepatology No. 2017 (2017), pp.1-6.
https://search.emarefa.net/detail/BIM-1141461
American Medical Association (AMA)
Chan, Yin& Pranke, Stephanie& Rashidi, Farid& Nosib, Shravan& Worobetz, Lawrence. Safety Profile of Liver FibroScan in Patients with Cardiac Pacemakers or Implantable Cardioverter-Defibrillators. Canadian Journal of Gastroenterology and Hepatology. 2017. Vol. 2017, no. 2017, pp.1-6.
https://search.emarefa.net/detail/BIM-1141461
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141461